This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
Clinical trial NCT07249879 · RECRUITING
Trial details
- NCT number
- NCT07249879
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-03
- Primary completion
- 2026-11-10
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.